📊 ALLR Key Takeaways
Is Allarity Therapeutics, Inc. (ALLR) a Good Investment?
Allarity is a development-stage pharmaceutical company with minimal revenue ($320K) and severe cash burn (-$14.8M operating cash flow), resulting in a cash runway of approximately 12 months at current burn rates. Negative margins across all metrics and inability to generate operating income create critical financial distress absent near-term product commercialization or external funding.
Allarity Therapeutics' fundamentals remain very weak: the company is generating negative revenue, deeply negative operating income, and substantial free cash outflows, which indicates the business is still far from a sustainable operating model. While the balance sheet is currently supported by a solid cash position and modest leverage, the ongoing cash burn materially outweighs those strengths and raises meaningful financing risk if commercialization or partnership progress does not improve.
Why Buy Allarity Therapeutics, Inc. Stock? ALLR Key Strengths
- Adequate short-term liquidity with 2.13x current ratio
- Manageable leverage ratio of 0.27x debt-to-equity
- $14.7M cash position provides near-term operational runway
- Strong near-term liquidity with $16.89M in cash and a 2.33x current ratio
- Low balance-sheet leverage with debt-to-equity of 0.22x
- Net loss and diluted EPS improved year over year, indicating some loss compression
ALLR Stock Risks: Allarity Therapeutics, Inc. Investment Risks
- Unsustainable cash burn of $14.8M per period with less than 12 months runway at current rate
- Negligible revenue generation ($320K) with negative gross profit indicates failed or pre-commercial product portfolio
- Severe operating losses (-$12.6M) and negative interest coverage (-123.6x) indicate inability to achieve profitability without major operational restructuring
- Dependent on clinical trial success, regulatory approval, and capital raises to survive
- Negative revenue and severely negative margins point to very poor underlying business quality
- Operating cash flow of -$11.58M and free cash flow of -$11.88M imply a short cash runway without improvement
- Negative ROE, negative ROA, and deeply negative interest coverage show weak profitability and limited financial resilience
Key Metrics to Watch
- Cash burn rate and remaining runway (critical)
- Revenue growth and product commercialization progress
- Clinical trial outcomes and regulatory milestone achievements
- Quarterly operating cash burn relative to cash on hand
- Revenue normalization and operating loss trend
Allarity Therapeutics, Inc. (ALLR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.13x current ratio provides a solid financial cushion.
ALLR Profit Margin, ROE & Profitability Analysis
ALLR vs Healthcare Sector: How Allarity Therapeutics, Inc. Compares
How Allarity Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Allarity Therapeutics, Inc. Stock Overvalued? ALLR Valuation Analysis 2026
Based on fundamental analysis, Allarity Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Allarity Therapeutics, Inc. Balance Sheet: ALLR Debt, Cash & Liquidity
ALLR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Allarity Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3,093.42 indicates the company is currently unprofitable.
ALLR Revenue Growth, EPS Growth & YoY Performance
Allarity Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALLR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Allarity Therapeutics, Inc. (CIK: 0001860657)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALLR
What is the AI rating for ALLR?
Allarity Therapeutics, Inc. (ALLR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALLR's key strengths?
Claude: Adequate short-term liquidity with 2.13x current ratio. Manageable leverage ratio of 0.27x debt-to-equity. ChatGPT: Strong near-term liquidity with $16.89M in cash and a 2.33x current ratio. Low balance-sheet leverage with debt-to-equity of 0.22x.
What are the risks of investing in ALLR?
Claude: Unsustainable cash burn of $14.8M per period with less than 12 months runway at current rate. Negligible revenue generation ($320K) with negative gross profit indicates failed or pre-commercial product portfolio. ChatGPT: Negative revenue and severely negative margins point to very poor underlying business quality. Operating cash flow of -$11.58M and free cash flow of -$11.88M imply a short cash runway without improvement.
What is ALLR's revenue and growth?
Allarity Therapeutics, Inc. reported revenue of $320.0K.
Does ALLR pay dividends?
Allarity Therapeutics, Inc. pays dividends, with $0.3M distributed to shareholders in the trailing twelve months.
Where can I find ALLR SEC filings?
Official SEC filings for Allarity Therapeutics, Inc. (CIK: 0001860657) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALLR's EPS?
Allarity Therapeutics, Inc. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALLR a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Allarity Therapeutics, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALLR stock overvalued or undervalued?
Valuation metrics for ALLR: ROE of -114.3% (sector avg: 15%), net margin of -3,509.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALLR stock in 2026?
Our dual AI analysis gives Allarity Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALLR's free cash flow?
Allarity Therapeutics, Inc.'s operating cash flow is $-14.8M, with capital expenditures of $8.0K. FCF margin is -4,633.8%.
How does ALLR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,509.7% (avg: 12%), ROE -114.3% (avg: 15%), current ratio 2.13 (avg: 2).